

## **Third Party Observations (TPOs) filed between January and December 2022**

Note:

TPO No. refers to publisher's internal reference number.

Appl. No. provides information on the International Application No. and the Publication Number.

National phase reflects information provided on WIPO's PATENTSCOPE database as at the date of preparing this document. However, this data is dynamic and may not provide accurate information on the actual status of the patent application.

TPO No.	165			
Appl. No.	WO2021047525			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021047525">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021047525</a>			
Applicants	中国医学科学院药物研究所 INSTITUTE OF MATERIA MEDICA ,CHINESE ACADEMY OF MEDICAL SCIENCES			
Priority Date	201910849215.3 09.09.2019 CN			
Details	TB: Applicant, Institute of Materia Medica, filed an application claiming maleate, fumarate, citrate and malate salts of a compound for the treatment of TB. The compound is most likely NTB-3119, a benzothiopyranone, that is under evaluation – see ( <a href="https://www.newtdrugs.org/pipeline/compound/ntb-3119">https://www.newtdrugs.org/pipeline/compound/ntb-3119</a> ). TPO was filed using 4 prior art documents in 3 notes, challenging novelty, and/or inventive step, inventive step only.			
Date of Filing of TPO	10/01/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	China	07.04.2022	202080070377.8	Published 19.08.2022
	Russian Federation	11.04.2022	2022107043	

TPO No.	166			
Appl. No.	WO2021048342			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021048342">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021048342</a>			
Applicants	JANSSEN SCIENCES IRELAND UNLIMITED COMPANY			
Priority Date	19197183.7 13.09.2019 EP			
Details	TB: Applicant, Janssen Sciences Ireland Unlimited Co., filed an application claiming imidazopyridines, imidazothiazoles, or tetrahydroimidazopyridines as bicyclic cores as anti bacterial compounds, for treatment of TB. TPO was filed in which 4 prior art documents were used in 3 notes for challenging inventive step.			
Date of Filing of TPO	13/01/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Canada	01.03.2022	<a href="#">3149868</a>	Published 13.04.2022
	United States of America	03.03.2022	17639963	Published 27.10.2022
	Brazil	08.03.2022	112022003799	
	China	11.03.2022	202080064727.X	Published 29.04.2022
	Japan	11.03.2022	2022516117	
	Mexico	11.03.2022	MX/a/2022/003037	Published 25.05.2022
	Republic of Korea	06.04.2022	<a href="#">1020227011475</a>	
	Australia	13.04.2022	<a href="#">2020346370</a>	
	European Patent Office	13.04.2022	<a href="#">2020776062</a>	Published 20.07.2022
	Russian Federation	13.04.2022	2022109579	

TPO No.	167			
Appl. No.	WO2021062119			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021062119">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021062119</a>			
Applicants	REGENTS OF THE UNIVERSITY OF MINNESOTA			
Priority Date	62/906,660 26.09.2019 US			
Details	HIV & HCV: Biologic: Applicant, Regents of the University of Minnesota, filed an application for NK engager compounds that bind viral antigens comprising IL-15 or a functional fragment thereof, and a targeting domain (TriKE) for targeting viral antigens. TPO was filed in which 1 prior art document was used in 1 note that challenged novelty &/or inventive step.			
Date of Filing of TPO	26/01/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Canada	15.03.2022	<a href="#">3151281</a>	Published 05.05.2022
	United States of America	21.03.2022	17762354	
	Australia	23.03.2022	<a href="#">2020354654</a>	
	Israel	23.03.2022	<a href="#">291646</a>	
	Japan	25.03.2022	2022519141	
	China	28.03.2022	202080067868.7	Published 13.05.2022
	Brazil	05.04.2022	112022005666	
	Republic of Korea	08.04.2022	<a href="#">1020227011781</a>	
	European Patent Office	26.04.2022	<a href="#">2020870067</a>	Published 17.08.2022
	India	26.04.2022	202217024399	Published 05.08.2022

TPO No.	168			
Appl. No.	WO2021058831			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021058831">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021058831</a>			
Applicants	UNIVERSIDAD DE ZARAGOZA			
Priority Date	19382827.4 26.09.2019 EP			
Details	TB: Biologic: Applicant, Universidad de Zaragoza, filed an application claiming live-attenuated Mycobacterium tuberculosis composition in the lyophilized form comprising an isolated microorganism belonging to MTBVAC strain for use in therapy of tuberculosis, asthma and other allergies via administration to a subject by an inhalation method using an aerosol technique. TPO was filed using 10 prior art documents in 5 notes, challenging novelty, and/or inventive step, inventive step only.			
Date of Filing of TPO	26/01/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Japan	24.03.2022	2022518930	
	Mexico	25.03.2022	MX/a/2022/003690	Published 12.08.2022
	United States of America	25.03.2022	17764127	
	Australia	30.03.2022	<a href="#">2020355198</a>	
	India	18.04.2022	202217022701	Published 29.07.2022
	European Patent Office	26.04.2022	<a href="#">2020790193</a>	
	China	25.05.2022	202080082198.6	Published 02.08.2022
	Canada		<a href="#">3155558</a>	Published 24.04.2022

TPO No.	169			
Appl. No.	WO2021064571			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021064571">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021064571</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/908,715 01.10.2019 US 62/925,300 24.10.2019 US			
Details	HIV: Applicant, ViiV Healthcare UK (No.5) Limited, filed an application claiming N-substituted 4-oxo-3-4- dihydropyrido pyrimidine derivatives as capsid inhibitors of HIV replication. TPO was filed using 10 prior art documents in 5 notes, challenging inventive step, and novelty and/inventive step.			
Date of Filing of TPO	01/02/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	23.03.2022	17763133	Published 08.12.2022
	Japan	31.03.2022	2022520234	
	European Patent Office	02.05.2022	<a href="#">2020789277</a>	Published 10.08.2022

TPO No.	170			
Appl. No.	WO2021064570			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021064570">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021064570</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/908,677 01.10.2019 US 62/924,781 23.10.2019 US 62/967,761 30.01.2020 US			
Details	HIV: Applicant, ViiV Healthcare UK (No.5) Limited, filed an application claiming substituted pyrimidone compounds as capsid inhibitors of HIV. TPO was filed in which 11 prior art documents were used in 5 notes for challenging inventive step.			
Date of Filing of TPO	01/02/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	24.03.2022	17763317	Published 29.12.2022
	Japan	31.03.2022	2022520238	
	European Patent Office	02.05.2022	<a href="#">2020789276</a>	Published 10.08.2022

TPO No.	171			
Appl. No.	WO2021064677			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021064677">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021064677</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/910,684 04.10.2019 US			
Details	HIV: Applicant, ViiV Healthcare UK (No.5) Limited filed an application claiming substituted quinazolinone compounds as capsid inhibitors. TPO was filed in which 10 prior art documents were used in 6 notes that challenged inventive step.			
Date of Filing of TPO	04/02/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	23.03.2022	17763161	Published 19.01.2023
	Japan	01.04.2022	2022520588	
	European Patent Office	04.05.2022	<a href="#">2020797180</a>	Published 10.08.2022



TPO No.	172			
Appl. No.	WO2021070054			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021070054">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021070054</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/912,215 08.10.2019 US			
Details	HIV: Applicant, ViiV Healthcare UK (No.5) Limited, filed an application claiming quinazoline or pyridopyrimidinone compounds as HIV capsid inhibitors. TPO was filed using 8 prior art documents in 8 notes, challenging inventive step or novelty, and/or inventive step.			
Date of Filing of TPO	08/02/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	29.03.2022	17764658	Published 24.11.2022
	Japan	07.04.2022	2022521353	
	European Patent Office	09.05.2022	<a href="#">2020792740</a>	Published 17.08.2022

TPO No.	173			
Appl. No.	WO2021076559			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021076559">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021076559</a>			
Applicants	THE SCRIPPS RESEARCH INSTITUTE ZWICK, Michael ZHANG, Lei IRIMIA, Adriana ZHU, Jiang WILSON, Ian			
Priority Date	62/914,640 14.10.2019 US			
Details	HIV: Biologic: Applicant, The Scripps Research Institute, filed an application claiming isolated monoclonal antibody or antigen-binding fragment binding to HIV Env gp-41 membrane proximal region (MPER) and engineered variants - PGZL1, an HIV - specific broadly neutralizing antibody. TPO was filed using 7 prior art documents in 6 notes, challenging inventive step.			
Date of Filing of TPO	14/02/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	European Patent Office	16.05.2022	<a href="#">2020877655</a>	Published 24.08.2022

TPO No.	174			
Appl. No.	WO2021087015			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021087015">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021087015</a>			
Applicants	INTERNATIONAL AIDS VACCINE INITIATIVE THE SCRIPPS RESEARCH INSTITUTE SOK, Devin BURTON, Dennis, R. JARDINE, Joseph, G.			
Priority Date	62/927,239 29.10.2019 US			
Details	HIV: Biologic: Applicant, International Aids Vaccine Initiative (IAVI) and The Scripps Research Institute, filed an application claiming engineered antibody or antigen binding fragment with modifications in the sequences of PGDM1400 antibody with enhanced neutralization capacity as compared to the parent PGDM1400. TPO was filed using 7 prior art documents in 4 notes, challenging inventive step.			
Date of Filing of TPO	28/02/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Canada	28.04.2022	<a href="#">3156626</a>	Published 10.06.2022
	United States of America	28.04.2022	17772561	Published 04.05.2023
	India	19.05.2022	202217028862	Published 02.09.2022
	European Patent Office	30.05.2022	<a href="#">2020883493</a>	Published 07.09.2022
	China	21.06.2022	202080089069.X	Published 22.11.2022

TPO No.	175			
Appl. No.	WO2021159044			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021159044">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021159044</a>			
Applicants	EMORY UNIVERSITY			
Priority Date	62/971,559 07.02.2020 US 62/988,133 11.03.2020 US 62/994,604 25.03.2020 US 63/006,625 07.04.2020 US			
Details	COVID 19: Applicant Emory University filed an application claiming N4-hydroxycytidine and its derivatives, esp. EIDD-1931, its ester, particularly prodrugs, to treat and / or prevent Covid-19 – application claiming a patent on <u>Molnuperavir, that has received Emergency Use Approval</u> . TPO was filed in which 7 prior art documents were used in 6 notes challenging novelty and inventive step. A Table of comparison and an additional note was also filed.			
Date of Filing of TPO	01/04/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Philippines	22.02.2022	12022550438	
	Costa Rica	24.02.2022	CR2022-000082	Published 01.07.2022
	Thailand	24.02.2022	2201001154	
	Dominican Republic	28.02.2022	DOP2022000049	Published 15.06.2022
	European Patent Office	22.03.2022	<a href="#">2021750787</a>	Published 29.06.2022
	India	16.05.2022	202217028094	Published 26.08.2022
	Eurasian Patent Organization	30.06.2022	<a href="#">202291843</a>	Published 31.10.2022
	Mexico	25.07.2022	<a href="#">MX/a/2022/009164</a>	Published 20.10.2022
	New Zealand	25.07.2022	790621	
	Japan	27.07.2022	2022545857	
	Israel	31.07.2022	<a href="#">295237</a>	
	Canada	04.08.2022	<a href="#">3167054</a>	Published 18.10.2022
	Peru	05.08.2022	001688-2022	Published 14.03.2023
	China	08.08.2022	202180013336.X	Published 31.01.2023
	Brazil	16.08.2022	112022015479	
	Republic of Korea	01.09.2022	<a href="#">1020227030290</a>	Published 17.10.2022
Georgia	05.09.2022	16034/1		
Saudi Arabia	19.12.2022	522440080		

TPO No.	176			
Appl. No.	WO2021127133			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021127133">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021127133</a>			
Applicants	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES			
Priority Date	62/948,939 17.12.2019 US			
Details	HIV: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services filed an application claiming nitroimidazole prodrug of a known mercaptobenzamide (HIV maturation inhibitor), and in combination with other therapeutic agents for HIV. TPO was filed in which 5 prior art documents in 4 notes were used challenging inventive step.			
Date of Filing of TPO	19/04/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	14.06.2022	17785155	Published 02.03.2023
	European Patent Office	18.07.2022	<a href="#">2020842420</a>	Published 26.10.2022

TPO No.	177			
Appl. No.	WO2021122996			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021122996">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021122996</a>			
Applicants	QURIENT CO., LTD.			
Priority Date	62/951,393 20.12.2019 US			
Details	TB: The Applicant QuriEnt Co. Ltd. filed an application claiming the pharmaceutical oral dosage form of Q203 ditosylate salt comprising granules & blend surrounding it, for treatment of TB and Buruli ulcer. TPO was filed in which 8 prior art documents were used in 4 notes to challenge novelty and inventive step.			
Date of Filing of TPO	20/04/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	27.04.2022	<a href="#">2020404130</a>	
	New Zealand	27.04.2022	787615	
	Philippines	25.05.2022	12022551281	
	United States of America	28.05.2022	17780969	Published 23.02.2023
	Canada	01.06.2022	<a href="#">3160393</a>	Published 10.08.2022
	China	10.06.2022	202080085924.X	Published 22.07.2022
	Israel	13.06.2022	<a href="#">293888</a>	
	Japan	17.06.2022	2022537481	
	European Patent Office	20.07.2022	<a href="#">2020839277</a>	Published 26.10.2022
	Russian Federation	20.07.2022	2022115957	
	Republic of Korea		<a href="#">1020227021262</a>	Published 25.08.2022

TPO No.	178			
Appl. No.	WO2021045836			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021045836">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021045836</a>			
Applicants	REGENERON PHARMACEUTICALS, INC.			
Priority Date	63/004,312 02.04.2020 US 63/014,687 23.04.2020 US 63/025,949 15.05.2020 US 63/034,865 04.06.2020 US			
Details	Biologic: COVID 19: The Applicant Regeneron Pharmaceuticals filed an application claiming Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments either alone or in combination with other therapeutic agent for treating or preventing viral infections (e.g., coronavirus infections). TPO was filed in which 10 prior art documents were used in 6 notes challenging inventive step. An additional note was also filed.			
Date of Filing of TPO	29/04/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Brazil	23.03.2021	112020015534	
	Singapore	01.04.2021	11202103404P	
	Israel	04.04.2021	<a href="#">282060</a>	
	Japan	05.04.2021	2021518800	
	Canada	06.04.2021	<a href="#">3115553</a>	Published 25.04.2021 Divisional 17.03.2023 Granted 25.04.2023
	Mexico	09.04.2021	MX/a/2021/004130	Published 13.07.2021
	Philippines	11.04.2021	12021550793	
	China	20.04.2021	202080005771.3	Published 07.12.2021
	Australia	21.04.2021	<a href="#">2020340881</a>	
	Eurasian Patent Organization	21.04.2021	<a href="#">202190836</a>	Published 31.10.2021
	New Zealand	21.04.2021	775303	Published 30.04.2021
	Thailand	30.04.2021	2101002512	
	Peru	28.09.2022	002139-2022	Published 13.12.2022
	Saudi Arabia	27.12.2022	522440749	
Republic of Korea		<a href="#">1020217013280</a>	Published 09.11.2021	

TPO No.	179			
Appl. No.	WO2021142150			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021142150">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021142150</a>			
Applicants	UNIVERSITY OF WASHINGTON			
Priority Date	62/959,077 09.01.2020 US			
Details	HIV: Applicant University of Washington filed an application claiming long acting injectables and homologous powdered form of known combinations of short-acting anti-retroviral drugs. TPO was filed in which 7 prior art documents were used in 5 notes challenging novelty and inventive step. An additional note was also filed.			
Date of Filing of TPO	09/05/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	China	24.06.2022	202180007622.5	Published 12.08.2022
	United States of America	07.07.2022	17791504	
	Brazil	19.07.2022	112022013452	
	India	01.08.2022	202247043940	Published 05.08.2022



TPO No.	180			
Appl. No.	WO2021154812.			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021154812&amp;_cid=P21-LLQS39-43900-1">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021154812&amp;_cid=P21-LLQS39-43900-1</a>			
Applicants	Novavax Inc			
Priority Date	16/997,001	19.08.2020	US	
	62/966,271	27.01.2020	US	
	62/976,858	14.02.2020	US	
	62/983,180	28.02.2020	US	
	63/048,945	07.07.2020	US	
	63/051,706	14.07.2020	US	
	63/054,182	20.07.2020	US	
	63/129,392	22.12.2020	US	
Details	COVID-19: Biologic: The Applicant Novavax Inc. filed an application claiming an immunogen comprising the coronavirus spike protein, with 2 proline substitutions, in the S2 unit, and modification in the furin cleavage site, signal peptide site, etc., claiming a nanoparticle composition with a buffer and saponin adjuvant – Matrix M1 & M2, to stimulate an immune response against SARS-COV2. TPO was filed in which 10 prior art documents in 7 notes were used challenging inventive step. An additional note was also filed. This application appears to be for the vaccine that has received Emergency Use Approval.			
Date of Filing of TPO	TPO and additional comments filed on 10/06/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	European Patent Office	09.03.2022	<a href="#">2020865848</a>	Published 15.06.2022

TPO No.	181			
Appl. No.	WO2021154763			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021154763">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021154763</a>			
Applicants	MODERNATX, INC.			
Priority Date	62/967,006 28.01.2020 US 62/971,825 07.02.2020 US 63/002,094 30.03.2020 US 63/009,005 13.04.2020 US 63/016,175 27.04.2020 US			
Details	COVID-19: Biologic: The Applicant Moderna TX filed an application claiming a mRNA vaccine comprising an open reading frame encoding the SARS-CoV2 protein, having consecutive 2 proline stabilizing mutations, 5'UTR & 3'UTR sequences and their modifications, modification of the uracil to 1-methyl pseudouridine, with lipid nanoparticles, etc. to be administered with at least 2 doses. TPO was filed in which 7 prior art documents were used in 6 notes to challenge inventive step. An additional note was also filed. This application appears to be for the vaccine mRNA-1273 that has received Emergency Use Approval.			
Date of Filing of TPO	30/05/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	19.07.2022	<a href="#">2021213108</a>	Withdrawn 12.01.2023
	New Zealand	19.07.2022	790471	Published 29.07.2022 Withdrawn 22.12.2022
	Israel	24.07.2022	<a href="#">295016</a>	Withdrawn 25.12.2022
	Philippines	26.07.2022	12022551910	
	Thailand	26.07.2022	2201004674	
	China	27.07.2022	202180011234.4	Published 11.10.2022
	Japan	27.07.2022	2022545900	
	Mexico	27.07.2022	MX/a/2022/009280	Published 09.09.2022
	Peru	27.07.2022	001511-2022	Published 11.11.2022
	United Arab Emirates	28.07.2022	P6001451/2022	
	Saudi Arabia	28.07.2022	522433457	Withdrawn 03.01.2023
	Brazil	09.08.2022	112022014837	
	Republic of Korea	17.08.2022	<a href="#">1020227028348</a>	Published 04.10.2022 Withdrawn 22.12.2022
Eurasian Patent Organization	24.08.2022	<a href="#">202292195</a>	Published 31.10.2022 Withdrawn 22.12.2022	

	European Patent Office	29.08.2022	<a href="#">2021706776</a>	Published 07.12.2022 Withdrawn 22.12.2022
	Russian Federation	29.08.2022	2022122735	Withdrawn 09.01.2023
	Canada		<a href="#">3168902</a>	Published 24.08.2022
	United States of America		17796208	Published 06.04.2023

TPO No.	182			
Appl. No.	WO2021155323			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021155323">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021155323</a>			
Applicants	BETH ISRAEL DEACONESS MEDICAL CENTER, INC. JANSSEN PHARMACEUTICALS, INC.			
Priority Date	3101131 28.11.2020 CA 62/705,187 15.06.2020 US 62/705,308 21.06.2020 US 62/706,366 12.08.2020 US 62/706,676 02.09.2020 US 62/706,937 18.09.2020 US 62/706,958 21.09.2020 US 62/969,008 31.01.2020 US 62/994,630 25.03.2020 US 63/014,467 23.04.2020 US 63/025,782 15.05.2020 US 63/043,090 23.06.2020 US 63/066,147 14.08.2020 US 63/112,900 12.11.2020 US 63/121,482 04.12.2020 US 63/133,969 05.01.2021 US 63/135,182 08.01.2021 US 63/141,913 26.01.2021 US 63/142,977 28.01.2021 US 63/198,089 28.09.2020 US 63/198,306 09.10.2020 US			
Details	<p>Biologic: COVID 19: The Applicants Beth Israel Deaconess Medica Centre, Inc. and Janssen Pharmaceuticals Inc. filed an application claiming isolated replication defective rAd26 vector comprising nucleic acid molecule encoding spike protein of SARS-CoV2, &amp; its variants – 2 consecutive proline substitutions, furin cleavage modifications, deletion of signal peptide, etc. linked to a CMV promoter, comprising at least 1 TetO motif, for immunization against COVID-19. TPO was filed in which 7 prior art documents were used in 5 notes challenging inventive step. An additional note was also filed. This application appears to be for the vaccine that has received Emergency Use Approval.</p>			
Date of Filing of TPO	31/05/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Japan	29.07.2022	2022546341	
	United States of America	29.07.2022	17759803	Published 09.03.2023
	Brazil	09.08.2022	112022014808	
	Eurasian Patent Organization	24.08.2022	<a href="#">202292199</a>	Published 28.02.2023
	European Patent Office	31.08.2022	<a href="#">2021747489</a>	Published 07.12.2022

	China	29.09.2022	202180025856.2	Published 09.05.2023
	Republic of Korea		<a href="#">1020227030114</a>	Published 05.10.2022

TPO No.	183			
Appl. No.	WO2021159040			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021159040">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021159040</a>			
Applicants	MODERNATX, INC.			
Priority Date	62/971,825 07.02.2020 US 63/016,175 27.04.2020 US 63/044,330 25.06.2020 US 63/063,137 07.08.2020 US			
Details	COVID-19: Biologic: The Applicant Moderna TX filed an application claiming a mRNA domain vaccine comprising an open reading frame encoding the SARS-CoV2 protein NTD and RBD, linked by PADRE, S1 subunit linked to S2 subunit, 5'UTR & 3'UTR sequences and their modifications, modification of the uracil to 1-methyl pseudouridine, with lipid nanoparticles, etc. to be administered to induce immune response. TPO was filed in which 7 prior art documents were used in 5 notes to challenge inventive step. An additional note was also filed. This application appears to be for the vaccine booster dose of Moderna - mRNA-1283 that has received Emergency Use Approval.			
Date of Filing of TPO	07/06/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Israel	04.08.2022	<a href="#">295377</a>	
	Canada	05.08.2022	<a href="#">3170150</a>	Published 01.09.2022
	Mexico	05.08.2022	MX/a/2022/009707	Published 20.10.2022
	China	08.08.2022	202180013506.4	Published 30.12.2022
	Japan	08.08.2022	2022548194	
	New Zealand	09.08.2022	791159	
	Brazil	16.08.2022	112022015565	
	European Patent Office	07.09.2022	<a href="#">2021709270</a>	Published 14.12.2022
	Russian Federation	07.09.2022	2022123676	
	Saudi Arabia	26.01.2023	522440077	
	Republic of Korea		<a href="#">1020227028371</a>	Published 18.10.2022

TPO No.	184			
Appl. No.	WO2021002776			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021002776">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021002776</a>			
Applicants	FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION			
Priority Date	2020114424 23.04.2020 RU			
Details	Biologic: COVID 19: The Applicants Federal State Budgetary Institution "National Research Centre For Epidemiology And Microbiology Named After The Honorary Academician N.F. Gamaleya" Of The Ministry Of Health Of The Russian Federation, filed an application claiming a recombinant hAd5 or hAd26 vector containing SARS-CoV2 antigen with C-terminal deletion of 18AA sequence, etc. for immunization against COVID-19. TPO was filed in which 10 prior art documents were used in 7 notes challenging inventive step. An additional note was also filed. This application appears to be for the Sputnik vaccine that has received Emergency Use Approval.			
Date of Filing of TPO	29/06/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Eurasian Patent Organization	23.12.2020	<a href="#">202000368</a>	Published 30.06.2021 Granted 30.06.2021
	United States of America	02.08.2021	17427745	Published 29.09.2022
	European Patent Office	14.02.2022	<a href="#">2020834701</a>	Published 15.06.2022
	United Arab Emirates	21.02.2022	P6000306/2022	
	Israel	21.02.2022	<a href="#">290787</a>	
	Mexico	21.02.2022	MX/a/2022/002194	Published 15.06.2022
	Philippines	02.03.2022	12022550521	
	Brazil	03.03.2022	112022003154	
	China	30.03.2022	202080068594.3	Published 13.09.2022
	India	30.03.2022	202227018996	Published 12.08.2022
	Japan	30.03.2022	2022520116	
	Saudi Arabia	15.12.2022	522431744	
	Canada		<a href="#">3156350</a>	Published 28.04.2022
Republic of Korea		08.08.2022	Published 09.01.2023	

TPO No.	185			
Appl. No.	WO2021176367			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021176367">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021176367</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/985,946 06.03.2020 US			
Details	HIV: The Applicant Viiv Healthcare UK limited filed an application claiming two compounds with pyridopyrimidinone ring scaffold, and its isomeric/ atropisomeric forms, its salts and pharmaceutical compositions as capsid inhibitors for treatment of HIV. TPO was filed in which 5 prior art documents were used in 3 notes to challenge inventive step.			
Date of Filing of TPO	06/07/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	22.08.2022	17801410	Published 06.04.2023
	Japan	05.09.2022	2022553214	
	European Patent Office	06.10.2022	<a href="#">2021711369</a>	Published 11.01.2023



TPO No.	186			
Appl. No.	WO2021176366			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021176366">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021176366</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/985,937 06.03.2020 US 63/040,051 17.06.2020 US			
Details	HIV: The Applicant, ViivHealthcare UK Ltd. filed an application claiming compounds with pyrido-pyrimidine scaffold and their pharmaceutical compositions as capsid inhibitors for the treatment of HIV. TPO was filed in which 6 prior art documents were used in 4 notes challenging inventive step.			
Date of Filing of TPO	06/07/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Canada	02.09.2022	<a href="#">3170536</a>	Published 18.11.2022
	Israel	04.09.2022	<a href="#">296182</a>	
	Japan	05.09.2022	2022553213	
	Mexico	05.09.2022	<a href="#">MX/a/2022/011016</a>	Published 13.12.2022
	Republic of Korea	05.10.2022	<a href="#">1020227034569</a>	Published 15.11.2022
	European Patent Office	06.10.2022	<a href="#">2021710351</a>	Published 11.01.2023
	Russian Federation	06.10.2022	2022125939	
	China	01.11.2022	202180032445.6	Published 31.12.2022

TPO No.	187			
Appl. No.	WO2021181100			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021181100">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021181100</a>			
Applicants	OXFORD UNIVERSITY INNOVATION LIMITED			
Priority Date	2003670.3	13.03.2020	GB	
	2006608.0	05.05.2020	GB	
	2007062.9	13.05.2020	GB	
	2009239.1	17.06.2020	GB	
	2010569.8	09.07.2020	GB	
	2016922.3	26.10.2020	GB	
	2017284.7	30.10.2020	GB	
	2017677.2	09.11.2020	GB	
	2018410.7	23.11.2020	GB	
	2018718.3	27.11.2020	GB	
	2100034.4	04.01.2021	GB	
Details	<p>Biologic: COVID19: The Applicant, Oxford University Innovation Ltd. filed an application claiming Chimpanzee Adenovirus - ChAdOX1 viral vectors as vaccine against SARS-CoV2. They claim a composition comprising the ChAdOx1 viral vector having a polynucleotide sequence encoding the native and codon optimised spike protein from the SARS-CoV2 (full length or only receptor binding domain), in fusion with tPA used to provide protective immunity, administered through different routes, as a single or double dose. TPO was filed in which 9 prior art documents were used in 7 notes challenging inventive step, and an additional comment was also filed. This appears to be the Oxford/ AstraZeneca vaccine that received Emergency Use Approval.</p>			
Date of Filing of TPO	13.07.2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Eurasian Patent Organisation	01.08.2022	<a href="#">202292030</a>	Published 31.12.2022
	New Zealand	05.08.2022	791094	
	Philippines	08.08.2022	12022552048	
	Israel	15.08.2022	<a href="#">295630</a>	
	Japan	19.08.2022	2022549978	
	China	22.08.2022	202180016017.4	Published 28.02.2023
	Peru	05.09.2022	001921-2022	Published 11.11.2022
	United Arab Emirates	06.09.2022	P6001778/2022	
	Thailand	12.09.2022	2201005748	
	Mexico	13.09.2022	<a href="#">MX/a/2022/011394</a>	Published 10.11.2022
	European Patent Office	13.10.2022	<a href="#">2021713080</a>	Published 18.01.2023
	Saudi Arabia	22.12.2022	522440255	

	Canada		<a href="#">3171939</a>	Published 18.09.2022
	Republic of Korea		<a href="#">1020227034118</a>	Published 15.11.2022

TPO No.	188			
Appl. No.	WO2021189047			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021189047">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021189047</a>			
Applicants	CODIAK BIOSCIENCES, INC			
Priority Date	63/001,088	27.03.2020	US	
	63/003,171	31.03.2020	US	
	63/006,585	07.04.2020	US	
	63/017,514	29.04.2020	US	
	63/142,418	27.01.2021	US	
	PCT/US2020/024023	20.03.2020	US	
Details	Biologic: COVID19: The Applicant, Codiak Bio Sciences Inc. filed an application claiming extracellular vesicles, engineered to carry scaffold proteins, comprising of at least one antigen of the SARS-CoV1, and/or SARS-CoV2, or other antigens, with adjuvants, immune modulator and targeting moiety for prevention of SARS-CoV2. TPO was used filing 7 prior art documents in 4 notes targeting inventive step. Codiak has received funding from CEPI for some of the claims covered in the application.			
Date of Filing of TPO	20/07/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	08.09.2022	<a href="#">2021236763</a>	
	Canada	13.09.2022	<a href="#">3171623</a>	Published 20.11.2022
	Japan	16.09.2022	2022556038	
	European Patent Office	20.10.2022	<a href="#">2021717740</a>	Published 25.01.2023

TPO No.	189			
Appl. No.	WO2021209900			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021209900">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021209900</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	63/010,196 14.04.2020 US 63/013,576 22.04.2020 US			
Details	HIV: The Applicant Viiv Healthcare UK limited filed an application claiming compounds with dihydroquinazoline (Formula 1a and 1b) & pyridopyrimidinone ring scaffold (Formula 1c and 1d) with fluorinated peripheral moieties, and its salts and pharmaceutical compositions as capsid inhibitors for treatment of HIV. TPO was filed in which 10 prior art documents were used in 10 notes to challenge inventive step. Of these 10 documents, 2 were documents filed after the priority date but before the filing date of the present application (Px documents).			
Date of Filing of TPO	15/08/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	28.09.2022	<a href="#">2021256166</a>	
	Israel	03.10.2022	<a href="#">297041</a>	
	Mexico	13.10.2022	MX/a/2022/012881	Published 13.12.2022
	United States of America	13.10.2022	17918654	Published 18.05.2023
	Japan	14.10.2022	2022562796	
	China	17.10.2022	202180029136.3	Published 25.01.2022
	Republic of Korea	10.11.2022	<a href="#">1020227039354</a>	Published 05.01.2023
	European Patent Office	15.11.2022	<a href="#">2021719985</a>	Published 22.02.2023
	Russian Federation	15.11.2022	2022129188	
	Canada		<a href="#">3173866</a>	Published 13.12.2022

TPO No.	190			
Appl. No.	WO2021213924			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021213924">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021213924</a>			
Applicants	BIONTECH SE			
Priority Date	PCT/EP2020/061239	22.04.2020	EP	
	PCT/EP2020/066968	18.06.2020	EP	
	PCT/EP2020/068174	26.06.2020	EP	
	PCT/EP2020/069805	13.07.2020	EP	
	PCT/EP2020/071733	31.07.2020	EP	
	PCT/EP2020/071839	03.08.2020	EP	
	PCT/EP2020/073668	24.08.2020	EP	
	PCT/EP2020/081544	09.11.2020	EP	
	PCT/EP2020/081981	12.11.2020	EP	
	PCT/EP2020/082601	18.11.2020	EP	
	PCT/EP2020/082989	20.11.2020	EP	
	PCT/EP2020/083435	25.11.2020	EP	
	PCT/EP2020/084342	02.12.2020	EP	
	PCT/EP2020/085145	08.12.2020	EP	
	PCT/EP2020/085653	10.12.2020	EP	
	PCT/EP2020/087844	23.12.2020	EP	
	PCT/EP2021/050027	04.01.2021	EP	
	PCT/EP2021/050874	15.01.2021	EP	
	PCT/EP2021/050875	15.01.2021	EP	
	PCT/EP2021/051772	26.01.2021	EP	
	PCT/EP2021/052572	03.02.2021	EP	
	PCT/EP2021/052716	04.02.2021	EP	
	PCT/EP2021/054622	24.02.2021	EP	
Details	<p>Biologic: COVID19: The Applicant, BioNTech SE. filed an application claiming an mRNA vaccine against SARS-CoV2. The RNA encoded the amino acid sequence comprising of SARS-CoV2 protein, immunogenic variants, fragments, with or without 2P substitutions, comprising secretory signal peptide having modified RNA with 5'cap, Poly A tail, and 3'UTR, in LNP or lipoplexes kit for intramuscular administration. TPO was filed in which 14 prior art documents were used in 10 notes challenging inventive step. <u>This appears to be the BioNTech/ Pfizer vaccine application that received Emergency Use Approval.</u></p>			
Date of Filing of TPO	22/08/2022			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	India	18.10.2022	202247059383	Published 28.10.2022
	Israel	19.10.2022	<a href="#">297419</a>	
	China	20.10.2022	202180029692.0	Published 17.03.2023

	Japan	20.10.2022	2022564006	
	Mexico	20.10.2022	<a href="#">MX/a/2022/013254</a>	Published 13.02.2023
	New Zealand	20.10.2022	793579	Published 28.10.2022
	European Patent Office	22.11.2022	<a href="#">2021720413</a>	Published 01.03.2023
	Russian Federation	22.11.2022	2022129815	
	Canada		<a href="#">3174215</a>	Published 24.01.2023
	Republic of Korea		<a href="#">1020227040676</a>	Published 31.01.2023

TPO No.	191
Appl. No.	WO2021222304
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021222304">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021222304</a>
Applicants	MODERNATX, INC.
Priority Date	63/016,250 27.04.2020 US 63/026,172 18.05.2020 US
Details	Biologic: COVID19: The Applicant, ModernaTX filed an application claiming the specific composition of mRNA vaccine. They claimed a composition comprising 50 mcg–250 mcg (specifically 50 mcg) of mRNA [modified chemically (1-methylpseudouridine) and having 5'Cap and poly A tail] comprising an open reading frame that encodes a SARS-CoV-2 prefusion stabilized spike (S) protein; and a LNP comprising a mixture of lipids that comprises an ionizable cationic lipid (compound 1, also referred to as SM-102), a non-cationic lipid (DSPC), a sterol (cholesterol), and a PEG-modified lipid (PEG2000 DMG); with buffering components and methods of administration as a vaccine. TPO was filed in which 12 prior art documents were used in 9 notes challenging novelty and/or inventive step. <u>This appears to be the composition of ModernaTX vaccine that received Emergency Use Approval.</u>
Date of Filing of TPO	29/08/2022
National Phase	No National Phase as of now



TPO No.	192																																						
Appl. No.	WO2021222935																																						
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021222935">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021222935</a>																																						
Applicants	THE ROCKEFELLER UNIVERSITY																																						
Priority Date	63/016,569	28.04.2020	US																																				
	63/021,387	07.05.2020	US																																				
	63/032,112	29.05.2020	US																																				
	63/038,384	12.06.2020	US																																				
	63/119,088	30.11.2020	US																																				
Details	Biologic: COVID19: The Applicant, Rockefeller University, filed an application claiming antibodies against SARS-CoV2, that neutralize multiple SARS-CoV 2 strains. The MAb is conjugated with a PEG, receptor, etc. TPO was used filing 14 prior art documents in 8 notes targeting inventive step. <u>The Applicant has received grants and awards from the National Institutes of Health for the compounds in this Application.</u>																																						
Date of Filing of TPO	29/08/2022																																						
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>Israel</td> <td>09.08.2021</td> <td><a href="#">285472</a></td> <td></td> </tr> <tr> <td>Japan</td> <td>11.08.2021</td> <td>2021547079</td> <td></td> </tr> <tr> <td>European Patent Office</td> <td>07.09.2021</td> <td><a href="#">2021727770</a></td> <td>Published 15.12.2021</td> </tr> <tr> <td>Russian Federation</td> <td>11.10.2021</td> <td>2021129497</td> <td>Published 11.04.2023</td> </tr> <tr> <td>Singapore</td> <td>17.11.2021</td> <td>11202112792W</td> <td></td> </tr> <tr> <td>Mexico</td> <td>06.12.2021</td> <td><a href="#">MX/a/2021/015024</a></td> <td>Published 09.02.2022</td> </tr> <tr> <td>Saudi Arabia</td> <td>25.05.2022</td> <td>521430235</td> <td></td> </tr> <tr> <td>Republic of Korea</td> <td></td> <td><a href="#">1020227003598</a></td> <td>Published 05.01.2023</td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	Israel	09.08.2021	<a href="#">285472</a>		Japan	11.08.2021	2021547079		European Patent Office	07.09.2021	<a href="#">2021727770</a>	Published 15.12.2021	Russian Federation	11.10.2021	2021129497	Published 11.04.2023	Singapore	17.11.2021	11202112792W		Mexico	06.12.2021	<a href="#">MX/a/2021/015024</a>	Published 09.02.2022	Saudi Arabia	25.05.2022	521430235		Republic of Korea		<a href="#">1020227003598</a>	Published 05.01.2023
Office	Entry Date	National Number	National Status																																				
Israel	09.08.2021	<a href="#">285472</a>																																					
Japan	11.08.2021	2021547079																																					
European Patent Office	07.09.2021	<a href="#">2021727770</a>	Published 15.12.2021																																				
Russian Federation	11.10.2021	2021129497	Published 11.04.2023																																				
Singapore	17.11.2021	11202112792W																																					
Mexico	06.12.2021	<a href="#">MX/a/2021/015024</a>	Published 09.02.2022																																				
Saudi Arabia	25.05.2022	521430235																																					
Republic of Korea		<a href="#">1020227003598</a>	Published 05.01.2023																																				

TPO No.	193		
Appl. No.	WO2021224946		
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021224946">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021224946</a>		
Applicants	BHARAT BIOTECH INTERNATIONAL LIMITED		
Priority Date	202041019441	07.05.2020	IN
Details	Biologic: COVID: The Applicant Bharat Biotech International Ltd., filed an application for a nasal immunization against SARS-CoV2, claiming vaccine composition comprising adenovirus vectors – human or chimpanzee, namely hAd5 or ChAd36, comprising the complete S protein, vector constructs & immunogenic compositions, such as buffer, stabilizer, salts, etc.. TPO was filed in which 19 prior art documents were used in 9 notes to challenge inventive step. This intra nasal vaccine has received emergency use approval in India and some other countries. The Applicant, Bharat Biotech has licensed this from the University of Washington.		

Date of Filing of TPO	07/09/2022
National Phase	No National Phase as of now

TPO No.	194																																																																		
Appl. No.	WO2021233834																																																																		
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021233834">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021233834</a>																																																																		
Applicants	ASTRAZENECA UK LIMITED																																																																		
Priority Date	63/026,121 17.05.2020 US																																																																		
Details	<p>Biologic: COVID19: The Applicant, AstraZeneca UK Ltd., filed an application claiming monoclonal antibodies against SARS-CoV2, wherein the antibody, or antigen binding fragment binds to the SARS-CoV2 spike protein receptor binding domain at non-overlapping epitopes. The application was for a cocktail of 2 mAbs – AZD7442 – tixagevimab, and AZD8895 / COV2-2196 – cilgavimab (AZD1061 – also identified as COV2-2130) marketed as Evusheld. TPO was filed in which 13 prior art documents were used in 8 notes challenging inventive step. This drug has received emergency use approval, and the claimed antibodies have been licensed from Vanderbilt University.</p>																																																																		
Date of Filing of TPO	19/09/2022																																																																		
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>Israel</td> <td>06.11.2022</td> <td><a href="#">297977</a></td> <td></td> </tr> <tr> <td>China</td> <td>14.11.2022</td> <td>202180035990.0</td> <td>Published 03.02.2023</td> </tr> <tr> <td>Philippines</td> <td>14.11.2022</td> <td>12022553106</td> <td></td> </tr> <tr> <td>Japan</td> <td>15.11.2022</td> <td>2022569523</td> <td></td> </tr> <tr> <td>Thailand</td> <td>15.11.2022</td> <td>2201007484</td> <td></td> </tr> <tr> <td>United Arab Emirates</td> <td>16.11.2022</td> <td>P6002401/2022</td> <td></td> </tr> <tr> <td>Mexico</td> <td>16.11.2022</td> <td><a href="#">MX/a/2022/014422</a></td> <td>Published 06.01.2023</td> </tr> <tr> <td>Peru</td> <td>17.11.2022</td> <td>002684-2022</td> <td></td> </tr> <tr> <td>Eurasian Patent Organization</td> <td>06.12.2022</td> <td><a href="#">202293221</a></td> <td>Published 31.03.2023</td> </tr> <tr> <td>Australia</td> <td>07.12.2022</td> <td><a href="#">2021275361</a></td> <td></td> </tr> <tr> <td>Republic of Korea</td> <td>15.12.2022</td> <td><a href="#">1020227044127</a></td> <td>Published 19.01.2023</td> </tr> <tr> <td>New Zealand</td> <td>15.12.2022</td> <td>795693</td> <td>Published 23.12.2022</td> </tr> <tr> <td>European Patent Office</td> <td>19.12.2022</td> <td><a href="#">2021727793</a></td> <td>Published 29.03.2023</td> </tr> <tr> <td>Saudi Arabia</td> <td>26.01.2023</td> <td>522441342</td> <td></td> </tr> <tr> <td>Canada</td> <td></td> <td><a href="#">3182150</a></td> <td>Published 11.12.2022</td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	Israel	06.11.2022	<a href="#">297977</a>		China	14.11.2022	202180035990.0	Published 03.02.2023	Philippines	14.11.2022	12022553106		Japan	15.11.2022	2022569523		Thailand	15.11.2022	2201007484		United Arab Emirates	16.11.2022	P6002401/2022		Mexico	16.11.2022	<a href="#">MX/a/2022/014422</a>	Published 06.01.2023	Peru	17.11.2022	002684-2022		Eurasian Patent Organization	06.12.2022	<a href="#">202293221</a>	Published 31.03.2023	Australia	07.12.2022	<a href="#">2021275361</a>		Republic of Korea	15.12.2022	<a href="#">1020227044127</a>	Published 19.01.2023	New Zealand	15.12.2022	795693	Published 23.12.2022	European Patent Office	19.12.2022	<a href="#">2021727793</a>	Published 29.03.2023	Saudi Arabia	26.01.2023	522441342		Canada		<a href="#">3182150</a>	Published 11.12.2022
Office	Entry Date	National Number	National Status																																																																
Israel	06.11.2022	<a href="#">297977</a>																																																																	
China	14.11.2022	202180035990.0	Published 03.02.2023																																																																
Philippines	14.11.2022	12022553106																																																																	
Japan	15.11.2022	2022569523																																																																	
Thailand	15.11.2022	2201007484																																																																	
United Arab Emirates	16.11.2022	P6002401/2022																																																																	
Mexico	16.11.2022	<a href="#">MX/a/2022/014422</a>	Published 06.01.2023																																																																
Peru	17.11.2022	002684-2022																																																																	
Eurasian Patent Organization	06.12.2022	<a href="#">202293221</a>	Published 31.03.2023																																																																
Australia	07.12.2022	<a href="#">2021275361</a>																																																																	
Republic of Korea	15.12.2022	<a href="#">1020227044127</a>	Published 19.01.2023																																																																
New Zealand	15.12.2022	795693	Published 23.12.2022																																																																
European Patent Office	19.12.2022	<a href="#">2021727793</a>	Published 29.03.2023																																																																
Saudi Arabia	26.01.2023	522441342																																																																	
Canada		<a href="#">3182150</a>	Published 11.12.2022																																																																

TPO No.	195																																						
Appl. No.	WO2021243122																																						
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021243122">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021243122</a>																																						
Applicants	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM THE TRUSTEES OF DARTMOUTH COLLEGE																																						
Priority Date	63/032,502 29.05.2020 US																																						
Details	Biologic: COVID19: The Applicant, Board of Regents, University of Texas, filed an application claiming an engineered protein comprising (i) engineered CoV S protein ectodomain having 6 Pro substitutions (HexaPro)(placed either in a flexible loop or at N-terminus of a helix) (ii) mutation that eliminates the furin cleavage site & fused or conjugated to a trimerization domain and an engineered CoV trimer based on the protein. TPO was filed in which 10 prior art documents were used in 7 notes challenging inventive step. An additional comment was also added with this TPO. This is a vaccine immunogen in the NDV-vectored vaccine under clinical trials.																																						
Date of Filing of TPO	29/09/2022																																						
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>Australia</td> <td>08.11.202</td> <td><a href="#">2021279079</a></td> <td></td> </tr> <tr> <td>Israel</td> <td>10.11.2022</td> <td><a href="#">298131</a></td> <td></td> </tr> <tr> <td>Thailand</td> <td>23.11.2022</td> <td>2201007628</td> <td></td> </tr> <tr> <td>Canada</td> <td>28.11.2022</td> <td><a href="#">3180554</a></td> <td>Published 08.02.2023</td> </tr> <tr> <td>Japan</td> <td>28.11.2022</td> <td>2022573585</td> <td></td> </tr> <tr> <td>Mexico</td> <td>28.11.2022</td> <td><a href="#">MX/a/2022/015040</a></td> <td>Published 10.03.2023</td> </tr> <tr> <td>European Patent Office</td> <td>02.01.2023</td> <td><a href="#">2021811955</a></td> <td>Published 05.04.2023</td> </tr> <tr> <td>Republic of Korea</td> <td></td> <td><a href="#">1020227042842</a></td> <td>Published 07.02.2023</td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	Australia	08.11.202	<a href="#">2021279079</a>		Israel	10.11.2022	<a href="#">298131</a>		Thailand	23.11.2022	2201007628		Canada	28.11.2022	<a href="#">3180554</a>	Published 08.02.2023	Japan	28.11.2022	2022573585		Mexico	28.11.2022	<a href="#">MX/a/2022/015040</a>	Published 10.03.2023	European Patent Office	02.01.2023	<a href="#">2021811955</a>	Published 05.04.2023	Republic of Korea		<a href="#">1020227042842</a>	Published 07.02.2023
Office	Entry Date	National Number	National Status																																				
Australia	08.11.202	<a href="#">2021279079</a>																																					
Israel	10.11.2022	<a href="#">298131</a>																																					
Thailand	23.11.2022	2201007628																																					
Canada	28.11.2022	<a href="#">3180554</a>	Published 08.02.2023																																				
Japan	28.11.2022	2022573585																																					
Mexico	28.11.2022	<a href="#">MX/a/2022/015040</a>	Published 10.03.2023																																				
European Patent Office	02.01.2023	<a href="#">2021811955</a>	Published 05.04.2023																																				
Republic of Korea		<a href="#">1020227042842</a>	Published 07.02.2023																																				

TPO No.	196																										
Appl. No.	WO2021247567																										
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021247567">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021247567</a>																										
Applicants	WASHINGTON UNIVERSITY																										
Priority Date	63/032,815	01.06.2020	US																								
	63/051,103	13.07.2020	US																								
	63/162,417	17.03.2021	US																								
Details	Biologic: COVID19: The Applicant Washington University (note they have tied up with Bharat Biotech International Ltd.), filed an application for an intranasal & immunogenic composition against SARS-CoV2, claiming vaccine composition comprising simian adenovirus vectors SAd36 with modified genome, S protein prefusion stabilized with K986P & V987P mutations, wherein the transgene encodes SARS CoV2 spike protein. TPO was filed in which 13 prior art documents were used in 8 notes to challenge inventive step. An Additional Comment was also filed.																										
Date of Filing of TPO	03/10/2022																										
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>Canada</td> <td>23.11.2022</td> <td><a href="#">3180064</a></td> <td>Published 07.02.2023</td> </tr> <tr> <td>Japan</td> <td>30.11.2022</td> <td>2022573756</td> <td></td> </tr> <tr> <td>Australia</td> <td>02.12.2022</td> <td><a href="#">2021285823</a></td> <td></td> </tr> <tr> <td>European Patent Office</td> <td>02.01.2023</td> <td><a href="#">2021817848</a></td> <td>Published 05.04.2023</td> </tr> <tr> <td>Republic of Korea</td> <td></td> <td><a href="#">1020227044997</a></td> <td>Published 08.03.2023</td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	Canada	23.11.2022	<a href="#">3180064</a>	Published 07.02.2023	Japan	30.11.2022	2022573756		Australia	02.12.2022	<a href="#">2021285823</a>		European Patent Office	02.01.2023	<a href="#">2021817848</a>	Published 05.04.2023	Republic of Korea		<a href="#">1020227044997</a>	Published 08.03.2023
Office	Entry Date	National Number	National Status																								
Canada	23.11.2022	<a href="#">3180064</a>	Published 07.02.2023																								
Japan	30.11.2022	2022573756																									
Australia	02.12.2022	<a href="#">2021285823</a>																									
European Patent Office	02.01.2023	<a href="#">2021817848</a>	Published 05.04.2023																								
Republic of Korea		<a href="#">1020227044997</a>	Published 08.03.2023																								

TPO No.	197																																																		
Appl. No.	WO2021076009																																																		
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021076009">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021076009</a>																																																		
Applicants	FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION																																																		
Priority Date	2020127979 22.08.2020 RU																																																		
Details	Biologic: COVID19: The Applicant, Gamelya Institute, filed an application for adenoviral vectored vaccines against SARS-COV2, claiming deletion of the E & E2 expression vector based on human adenoviral AD26 and Ad5, each integrated into an expression cassette containing promoters CMV, CAG or EFI along with polyadenylation signal BGH or SV40, hAd26 vector with E4 ORF-6 region replaced with ORF6-Ad5, parental sequence of AD5 and AD26. TPO was filed in which 17 prior art documents were used in 10 notes challenging novelty/ inventive step. An additional comment was also added with this TPO. This is the Sputnik vaccine that received emergency approval.																																																		
Date of Filing of TPO	20/10/2022																																																		
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>Eurasian Patent Organization</td> <td>23.12.2020</td> <td><a href="#">202000369</a></td> <td>Published 31.03.2021 Granted 31.03.2021</td> </tr> <tr> <td>European Patent Office</td> <td>14.02.2022</td> <td><a href="#">2020877055</a></td> <td>Published 15.06.2022</td> </tr> <tr> <td>India</td> <td>24.02.2022</td> <td>202227010044</td> <td>Published 08.07.2022</td> </tr> <tr> <td>Japan</td> <td>25.02.2022</td> <td>2022513579</td> <td></td> </tr> <tr> <td>Israel</td> <td>01.03.2022</td> <td><a href="#">291022</a></td> <td></td> </tr> <tr> <td>Philippines</td> <td>01.03.2022</td> <td>12022550513</td> <td></td> </tr> <tr> <td>United Arab Emirates</td> <td>02.03.2022</td> <td>P6000372/2022</td> <td></td> </tr> <tr> <td>China</td> <td>02.03.2022</td> <td>202080061936.9</td> <td>Published 02.08.2022</td> </tr> <tr> <td>Mexico</td> <td>02.03.2022</td> <td><a href="#">MX/a/2022/002609</a></td> <td>Published 12.07.2022</td> </tr> <tr> <td>Brazil</td> <td>08.03.2022</td> <td>112022003581</td> <td></td> </tr> <tr> <td>Saudi Arabia</td> <td>15.12.2022</td> <td>522431814</td> <td></td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	Eurasian Patent Organization	23.12.2020	<a href="#">202000369</a>	Published 31.03.2021 Granted 31.03.2021	European Patent Office	14.02.2022	<a href="#">2020877055</a>	Published 15.06.2022	India	24.02.2022	202227010044	Published 08.07.2022	Japan	25.02.2022	2022513579		Israel	01.03.2022	<a href="#">291022</a>		Philippines	01.03.2022	12022550513		United Arab Emirates	02.03.2022	P6000372/2022		China	02.03.2022	202080061936.9	Published 02.08.2022	Mexico	02.03.2022	<a href="#">MX/a/2022/002609</a>	Published 12.07.2022	Brazil	08.03.2022	112022003581		Saudi Arabia	15.12.2022	522431814	
Office	Entry Date	National Number	National Status																																																
Eurasian Patent Organization	23.12.2020	<a href="#">202000369</a>	Published 31.03.2021 Granted 31.03.2021																																																
European Patent Office	14.02.2022	<a href="#">2020877055</a>	Published 15.06.2022																																																
India	24.02.2022	202227010044	Published 08.07.2022																																																
Japan	25.02.2022	2022513579																																																	
Israel	01.03.2022	<a href="#">291022</a>																																																	
Philippines	01.03.2022	12022550513																																																	
United Arab Emirates	02.03.2022	P6000372/2022																																																	
China	02.03.2022	202080061936.9	Published 02.08.2022																																																
Mexico	02.03.2022	<a href="#">MX/a/2022/002609</a>	Published 12.07.2022																																																
Brazil	08.03.2022	112022003581																																																	
Saudi Arabia	15.12.2022	522431814																																																	

TPO No.	198																																																										
Appl. No.	WO2022008643																																																										
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022008643">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022008643</a>																																																										
Applicants	JANSSEN PHARMACEUTICA NV																																																										
Priority Date	20185105.2 09.07.2020 EP																																																										
Details	TB: The Applicant Janssen Pharmaceuticals NV filed three applications, one of which claimed pharmaceutical compositions of Bedaquiline (BDQ), it's fumarate salt as micro/nanoparticles, with surface modifiers such as PEG4000, poloxamers, TPGS, etc. & specific ranges of each of the compositions, as long acting agents for treating TB, MDR TB, and . TPO was filed in which 8 prior art documents were used in 6 notes to challenge inventive step.																																																										
Date of Filing of TPO	09/11/2022																																																										
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>Canada</td> <td>12.12.2022</td> <td><a href="#">3182425</a></td> <td>Published 21.02.2023</td> </tr> <tr> <td>United States of America</td> <td>05.01.2023</td> <td>18004336</td> <td></td> </tr> <tr> <td>China</td> <td>06.01.2023</td> <td>202180049752.5</td> <td>Published 28.03.2023</td> </tr> <tr> <td>Japan</td> <td>06.01.2023</td> <td>2023500995</td> <td></td> </tr> <tr> <td>Mexico</td> <td>06.01.2023</td> <td><a href="#">MX/a/2023/000439</a></td> <td>Published 10.03.2023</td> </tr> <tr> <td>Thailand</td> <td>06.01.2023</td> <td>2301000102</td> <td></td> </tr> <tr> <td>Peru</td> <td>09.01.2023</td> <td>000037-2023</td> <td></td> </tr> <tr> <td>Saudi Arabia</td> <td>09.01.2023</td> <td>523442092</td> <td></td> </tr> <tr> <td>Eurasian Patent Organization</td> <td>03.02.2023</td> <td><a href="#">202390258</a></td> <td>Published 30.04.2023</td> </tr> <tr> <td>Australia</td> <td>08.02.2023</td> <td><a href="#">2021303490</a></td> <td></td> </tr> <tr> <td>Republic of Korea</td> <td>08.02.2023</td> <td><a href="#">1020237004632</a></td> <td>Published 20.03.2023</td> </tr> <tr> <td>European Patent Office</td> <td>09.02.2023</td> <td><a href="#">2021740063</a></td> <td>Published 17.05.2023</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	Canada	12.12.2022	<a href="#">3182425</a>	Published 21.02.2023	United States of America	05.01.2023	18004336		China	06.01.2023	202180049752.5	Published 28.03.2023	Japan	06.01.2023	2023500995		Mexico	06.01.2023	<a href="#">MX/a/2023/000439</a>	Published 10.03.2023	Thailand	06.01.2023	2301000102		Peru	09.01.2023	000037-2023		Saudi Arabia	09.01.2023	523442092		Eurasian Patent Organization	03.02.2023	<a href="#">202390258</a>	Published 30.04.2023	Australia	08.02.2023	<a href="#">2021303490</a>		Republic of Korea	08.02.2023	<a href="#">1020237004632</a>	Published 20.03.2023	European Patent Office	09.02.2023	<a href="#">2021740063</a>	Published 17.05.2023				
Office	Entry Date	National Number	National Status																																																								
Canada	12.12.2022	<a href="#">3182425</a>	Published 21.02.2023																																																								
United States of America	05.01.2023	18004336																																																									
China	06.01.2023	202180049752.5	Published 28.03.2023																																																								
Japan	06.01.2023	2023500995																																																									
Mexico	06.01.2023	<a href="#">MX/a/2023/000439</a>	Published 10.03.2023																																																								
Thailand	06.01.2023	2301000102																																																									
Peru	09.01.2023	000037-2023																																																									
Saudi Arabia	09.01.2023	523442092																																																									
Eurasian Patent Organization	03.02.2023	<a href="#">202390258</a>	Published 30.04.2023																																																								
Australia	08.02.2023	<a href="#">2021303490</a>																																																									
Republic of Korea	08.02.2023	<a href="#">1020237004632</a>	Published 20.03.2023																																																								
European Patent Office	09.02.2023	<a href="#">2021740063</a>	Published 17.05.2023																																																								

TPO No.	199																						
Appl. No.	WO2022008645																						
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022008645">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022008645</a>																						
Applicants	JANSSEN PHARMACEUTICA NV																						
Priority Date	20185108.6 09.07.2020 EP																						
Details	<p>TB: The Applicant, Janssen Pharmaceuticals NV, filed another application for BDQ, and its fumarate salt as micro/nano particles, one or more poloxamer as surface modifier, specific ranges of the components for manufacture of medicament for long-term treatment of MTb, M.leprae, administered at 1 to 2 weeks interval. TPO was filed in which 2 prior art documents were used in 2 notes challenging novelty, and/or inventive step.</p> <p>The third application by Janssen, WO2022008644, was similarly for the composition claiming PEG4000, poloxamers, TPGS, etc as surface modifiers, with specific ranges of each of them. The TPO was ready to be filed with 5 prior art documents in 3 notes. However, the same could not be filed due to technical glitches, and the time up for filing of the TPO. However, the other two applications for which TPO was filed were primarily the long-acting drugs of BDQ for treating TB.</p>																						
Date of Filing of TPO	09/11/2022																						
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>Canada</td> <td>24.12.2022</td> <td><a href="#">3182854</a></td> <td>Published 22.02.2023</td> </tr> <tr> <td>Japan</td> <td>05.01.2023</td> <td>2023500269</td> <td></td> </tr> <tr> <td>China</td> <td>06.01.2023</td> <td>202180048543.9</td> <td>Published 10.03.2023</td> </tr> <tr> <td>European Patent Office</td> <td>09.02.2023</td> <td><a href="#">2021742111</a></td> <td>Published 17.05.2023</td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	Canada	24.12.2022	<a href="#">3182854</a>	Published 22.02.2023	Japan	05.01.2023	2023500269		China	06.01.2023	202180048543.9	Published 10.03.2023	European Patent Office	09.02.2023	<a href="#">2021742111</a>	Published 17.05.2023
Office	Entry Date	National Number	National Status																				
Canada	24.12.2022	<a href="#">3182854</a>	Published 22.02.2023																				
Japan	05.01.2023	2023500269																					
China	06.01.2023	202180048543.9	Published 10.03.2023																				
European Patent Office	09.02.2023	<a href="#">2021742111</a>	Published 17.05.2023																				



TPO No.	200																																																		
Appl. No.	WO2022020242																																																		
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022020242">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022020242</a>																																																		
Applicants	ENANTA PHARMACEUTICALS, INC.																																																		
Priority Date	63/054,048 20.07.2020 US																																																		
Details	<p>COVID19: Enanta Pharmaceuticals filed an application for peptidomimetic compounds as 3CL protease inhibitors of COVID19. A TPO was filed using 6 prior art documents in 5 notes challenging inventive step. An additional note was also filed.</p> <p>It maybe noted that Enanta has filed an infringement suit against Pfizer for the drug Paxlovid based on this application.</p>																																																		
Date of Filing of TPO	21/11/2022																																																		
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>European Patent Office</td> <td>02.06.2022</td> <td><a href="#">2021846991</a></td> <td>Published 07.09.2022</td> </tr> <tr> <td>Germany</td> <td>23.08.2022</td> <td><a href="#">112021000413</a></td> <td>Published 01.12.2022 Granted 23.02.2023</td> </tr> <tr> <td>Spain</td> <td>25.08.2022</td> <td>P202290062</td> <td></td> </tr> <tr> <td>Italy</td> <td>22.09.2022</td> <td>112022000136383</td> <td></td> </tr> <tr> <td>Australia</td> <td>06.01.2023</td> <td><a href="#">2021313130</a></td> <td></td> </tr> <tr> <td>Thailand</td> <td>16.02.2023</td> <td>2301000257</td> <td></td> </tr> <tr> <td>Mexico</td> <td>17.02.2023</td> <td><a href="#">MX/a/2023/000798</a></td> <td>Published 10.03.2023</td> </tr> <tr> <td>Israel</td> <td>18.01.2023</td> <td><a href="#">300027</a></td> <td></td> </tr> <tr> <td>Japan</td> <td>19.01.2023</td> <td>2023504063</td> <td></td> </tr> <tr> <td>Republic of Korea</td> <td>15.02.2023</td> <td><a href="#">1020237005438</a></td> <td>Published 18.05.2023</td> </tr> <tr> <td>Canada</td> <td></td> <td><a href="#">3173964</a></td> <td>Published 13.12.2022</td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	European Patent Office	02.06.2022	<a href="#">2021846991</a>	Published 07.09.2022	Germany	23.08.2022	<a href="#">112021000413</a>	Published 01.12.2022 Granted 23.02.2023	Spain	25.08.2022	P202290062		Italy	22.09.2022	112022000136383		Australia	06.01.2023	<a href="#">2021313130</a>		Thailand	16.02.2023	2301000257		Mexico	17.02.2023	<a href="#">MX/a/2023/000798</a>	Published 10.03.2023	Israel	18.01.2023	<a href="#">300027</a>		Japan	19.01.2023	2023504063		Republic of Korea	15.02.2023	<a href="#">1020237005438</a>	Published 18.05.2023	Canada		<a href="#">3173964</a>	Published 13.12.2022
Office	Entry Date	National Number	National Status																																																
European Patent Office	02.06.2022	<a href="#">2021846991</a>	Published 07.09.2022																																																
Germany	23.08.2022	<a href="#">112021000413</a>	Published 01.12.2022 Granted 23.02.2023																																																
Spain	25.08.2022	P202290062																																																	
Italy	22.09.2022	112022000136383																																																	
Australia	06.01.2023	<a href="#">2021313130</a>																																																	
Thailand	16.02.2023	2301000257																																																	
Mexico	17.02.2023	<a href="#">MX/a/2023/000798</a>	Published 10.03.2023																																																
Israel	18.01.2023	<a href="#">300027</a>																																																	
Japan	19.01.2023	2023504063																																																	
Republic of Korea	15.02.2023	<a href="#">1020237005438</a>	Published 18.05.2023																																																
Canada		<a href="#">3173964</a>	Published 13.12.2022																																																

TPO No.	201																																																														
Appl. No.	WO2022031894																																																														
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022031894">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022031894</a>																																																														
Applicants	GILEAD SCIENCES, INC.																																																														
Priority Date	63/062,899 07.08.2020 US																																																														
Details	HIV: The Applicant Gilead filed an application claiming phosphorodiamidate prodrugs of tenofovir. The specifically claimed Markush structures and compounds have a dimethyl glycine amino acid ester with terminal alkyl, cycloalkyl, spiroalkyl, etc. moieties. TPO was filed in which 8 prior art documents were used in 7 notes to challenge inventive step.																																																														
Date of Filing of TPO	07/12/2022																																																														
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>Canada</td> <td>13.01.2023</td> <td><a href="#">3186054</a></td> <td>Published 14.03.2023</td> </tr> <tr> <td>Israel</td> <td>17.01.2023</td> <td><a href="#">299980</a></td> <td></td> </tr> <tr> <td>Thailand</td> <td>02.02.2023</td> <td>2301000605</td> <td></td> </tr> <tr> <td>Mexico</td> <td>03.02.2023</td> <td><a href="#">MX/a/2023/001507</a></td> <td>Published 13.04.2023</td> </tr> <tr> <td>China</td> <td>06.03.2023</td> <td>202180057176.9</td> <td>Published 30.05.2023</td> </tr> <tr> <td>Japan</td> <td>06.03.2023</td> <td>2023507948</td> <td></td> </tr> <tr> <td>Peru</td> <td>06.03.2023</td> <td>000221-2023</td> <td></td> </tr> <tr> <td>United States of America</td> <td>06.03.2023</td> <td>18040782</td> <td></td> </tr> <tr> <td>Saudi Arabia</td> <td>07.02.2023</td> <td>523442468</td> <td></td> </tr> <tr> <td>Eurasian Patent Organization</td> <td>26.03.2023</td> <td><a href="#">202390439</a></td> <td>Published 30.04.2023</td> </tr> <tr> <td>Australia</td> <td>06.03.2023</td> <td><a href="#">2021320236</a></td> <td></td> </tr> <tr> <td>Republic of Korea</td> <td>06.03.2023</td> <td><a href="#">1020237007868</a></td> <td>Published 10.04.2023</td> </tr> <tr> <td>New Zealand</td> <td>06.03.2023</td> <td>797870</td> <td>Published 31.03.2023</td> </tr> <tr> <td>European Patent Office</td> <td>07.03.2023</td> <td><a href="#">2021762257</a></td> <td>Published 14.06.2023</td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	Canada	13.01.2023	<a href="#">3186054</a>	Published 14.03.2023	Israel	17.01.2023	<a href="#">299980</a>		Thailand	02.02.2023	2301000605		Mexico	03.02.2023	<a href="#">MX/a/2023/001507</a>	Published 13.04.2023	China	06.03.2023	202180057176.9	Published 30.05.2023	Japan	06.03.2023	2023507948		Peru	06.03.2023	000221-2023		United States of America	06.03.2023	18040782		Saudi Arabia	07.02.2023	523442468		Eurasian Patent Organization	26.03.2023	<a href="#">202390439</a>	Published 30.04.2023	Australia	06.03.2023	<a href="#">2021320236</a>		Republic of Korea	06.03.2023	<a href="#">1020237007868</a>	Published 10.04.2023	New Zealand	06.03.2023	797870	Published 31.03.2023	European Patent Office	07.03.2023	<a href="#">2021762257</a>	Published 14.06.2023
Office	Entry Date	National Number	National Status																																																												
Canada	13.01.2023	<a href="#">3186054</a>	Published 14.03.2023																																																												
Israel	17.01.2023	<a href="#">299980</a>																																																													
Thailand	02.02.2023	2301000605																																																													
Mexico	03.02.2023	<a href="#">MX/a/2023/001507</a>	Published 13.04.2023																																																												
China	06.03.2023	202180057176.9	Published 30.05.2023																																																												
Japan	06.03.2023	2023507948																																																													
Peru	06.03.2023	000221-2023																																																													
United States of America	06.03.2023	18040782																																																													
Saudi Arabia	07.02.2023	523442468																																																													
Eurasian Patent Organization	26.03.2023	<a href="#">202390439</a>	Published 30.04.2023																																																												
Australia	06.03.2023	<a href="#">2021320236</a>																																																													
Republic of Korea	06.03.2023	<a href="#">1020237007868</a>	Published 10.04.2023																																																												
New Zealand	06.03.2023	797870	Published 31.03.2023																																																												
European Patent Office	07.03.2023	<a href="#">2021762257</a>	Published 14.06.2023																																																												

TPO No.	202
Appl. No.	WO2022035860
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022035860">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022035860</a>
Applicants	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES INTERNATIONAL AIDS VACCINE INITIATIVE THE SCRIPPS RESEARCH INSTITUTE EMERGENT TRAVEL HEALTH INC.
Priority Date	63/063,810 10.08.2020 US
Details	HIV: The Applicant, Scripps Research Institute & IAVI, filed an application claiming replication competent Ad4 vectored vaccine for HIV, comprising HIV 1 Clade C strain 1086 immunogens Env150KN or Env145NFL. TPO was filed in which 7 prior art documents were used in 4 notes challenging novelty, and/or inventive step.
Date of Filing of TPO	12/12/2022
National Phase	No National Phase as of now

TPO No.	203																																		
Appl. No.	WO2022034044																																		
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022034044">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022034044</a>																																		
Applicants	ASTRAZENECA UK LIMITED																																		
Priority Date	63/063,862 10.08.2020 US 63/112,104 10.11.2020 US																																		
Details	<p>COVID19: The Applicant, Astra Zeneca, filed an application for method of treating or preventing COVID19 by specific doses of SARS-CoV2 antibodies – 2196 + 2130. A TPO was filed using 7 prior art documents in 5 notes challenging inventive step. The Application relates to Evusheld which has received EUA in the US, EU and other countries. Though the USFDA has issued warnings regarding the effectiveness of this cocktail against the variants, a TPO was filed as it is still approved in other countries.</p>																																		
Date of Filing of TPO	12/12/2022																																		
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>Israel</td> <td>29.01.2023</td> <td><a href="#">300257</a></td> <td></td> </tr> <tr> <td>Saudi Arabia</td> <td>09.02.2023</td> <td>523442505</td> <td></td> </tr> <tr> <td>Eurasian Patent Organization</td> <td>27.02.2023</td> <td><a href="#">202390461</a></td> <td>Published 31.05.2023</td> </tr> <tr> <td>Australia</td> <td>02.03.2023</td> <td><a href="#">2021325339</a></td> <td></td> </tr> <tr> <td>Republic of Korea</td> <td>08.03.2023</td> <td><a href="#">1020237008224</a></td> <td>Published 04.04.2023</td> </tr> <tr> <td>European Patent Office</td> <td>10.03.2023</td> <td><a href="#">2021763274</a></td> <td>Published 14.06.2023</td> </tr> <tr> <td>Canada</td> <td></td> <td><a href="#">3190280</a></td> <td>Published 22.02.2023</td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	Israel	29.01.2023	<a href="#">300257</a>		Saudi Arabia	09.02.2023	523442505		Eurasian Patent Organization	27.02.2023	<a href="#">202390461</a>	Published 31.05.2023	Australia	02.03.2023	<a href="#">2021325339</a>		Republic of Korea	08.03.2023	<a href="#">1020237008224</a>	Published 04.04.2023	European Patent Office	10.03.2023	<a href="#">2021763274</a>	Published 14.06.2023	Canada		<a href="#">3190280</a>	Published 22.02.2023
Office	Entry Date	National Number	National Status																																
Israel	29.01.2023	<a href="#">300257</a>																																	
Saudi Arabia	09.02.2023	523442505																																	
Eurasian Patent Organization	27.02.2023	<a href="#">202390461</a>	Published 31.05.2023																																
Australia	02.03.2023	<a href="#">2021325339</a>																																	
Republic of Korea	08.03.2023	<a href="#">1020237008224</a>	Published 04.04.2023																																
European Patent Office	10.03.2023	<a href="#">2021763274</a>	Published 14.06.2023																																
Canada		<a href="#">3190280</a>	Published 22.02.2023																																

TPO No.	204		
Appl. No.	WO2022038642		
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022038642">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022038642</a>		
Applicants	BHARAT BIOTECH INTERNATIONAL LIMITED		
Priority Date	202041007559 21.08.2020 IN		
Details	<p>COVID19: The Applicant, Bharat Biotech International Limited, filed an application for method of manufacturing an inactivated SARS-CoV2 vaccine. A TPO was filed using 8 prior art documents in 5 notes challenging novelty, and/or inventive step. An additional note was also filed.</p> <p>This application appears to be for the manufacturing process of the EUA vaccine called Covaxin.</p>		
Date of Filing of TPO	21/12/2022		
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>
	European Patent Office	21.03.2023	<a href="#">2021857952</a>
			<b>National Status</b> Published 28.06.2023

TPO No.	205																																		
Appl. No.	<a href="#">WO2021076010</a>																																		
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021076010&amp;_cid=P21-LLQSAR-46339-1">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021076010&amp;_cid=P21-LLQSAR-46339-1</a>																																		
Applicants	FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION																																		
Priority Date	2020127980 22.08.2020 RU																																		
Details	COVID19: The Applicant, National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation filed an application for an agent comprising 2 components, which may be rAd26 and rAd5, rAd26 and simian Ad25 (sAd25), or sAd25 and rAd5, each with claimed expression cassette for use to induce specific immunity against SARS-CoV-2. A TPO was filed using 17 prior art documents in 10 notes challenging novelty, and/or inventive step. An additional note was also filed.																																		
Date of Filing of TPO	TPO and additional comments filed on 3/1/2023																																		
National Phase	<table border="1"> <thead> <tr> <th>Office</th> <th>Entry Date</th> <th>National Number</th> <th>National Status</th> </tr> </thead> <tbody> <tr> <td>European Patent Office</td> <td>31.03.2023</td> <td><a href="#">2020956902</a></td> <td>Published 05.07.2023</td> </tr> <tr> <td>Mexico</td> <td>03.04.2023</td> <td><a href="#">MX/a/2023/003938</a></td> <td></td> </tr> <tr> <td>Israel</td> <td>04.04.2023</td> <td><a href="#">301943</a></td> <td></td> </tr> <tr> <td>Canada</td> <td>05.04.2023</td> <td><a href="#">3194959</a></td> <td>Published 10.05.2023</td> </tr> <tr> <td>Peru</td> <td>05.04.2023</td> <td>001366-2023</td> <td></td> </tr> <tr> <td>Republic of Korea</td> <td>04.05.2023</td> <td><a href="#">1020237015417</a></td> <td></td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>			Office	Entry Date	National Number	National Status	European Patent Office	31.03.2023	<a href="#">2020956902</a>	Published 05.07.2023	Mexico	03.04.2023	<a href="#">MX/a/2023/003938</a>		Israel	04.04.2023	<a href="#">301943</a>		Canada	05.04.2023	<a href="#">3194959</a>	Published 10.05.2023	Peru	05.04.2023	001366-2023		Republic of Korea	04.05.2023	<a href="#">1020237015417</a>					
Office	Entry Date	National Number	National Status																																
European Patent Office	31.03.2023	<a href="#">2020956902</a>	Published 05.07.2023																																
Mexico	03.04.2023	<a href="#">MX/a/2023/003938</a>																																	
Israel	04.04.2023	<a href="#">301943</a>																																	
Canada	05.04.2023	<a href="#">3194959</a>	Published 10.05.2023																																
Peru	05.04.2023	001366-2023																																	
Republic of Korea	04.05.2023	<a href="#">1020237015417</a>																																	